Universal Genetic Testing in Breast Cancer Further Supported in New Invitae-Led Study

NCCN has since updated its guidelines to additionally recommend genetic testing of patients with triple-negative breast cancer; for PARP inhibitor treatment eligibility in metastatic disease for high-risk patients with ERBB2-negative disease; and if a patient has a greater than 5 percent chance of a BRCA1 or BRCA2 variant based on an assessment tool like BRCAPRO.

However, these new guidelines fall short of universal germline genetic testing, although other expert organizations such as the American Society of Breast Surgeons (ASBrS) do recommend universal testing.

Source: https://www.genomeweb.com/cancer/universal-genetic-testing-breast-cancer-further-supported-new-invitae-led-study